Reducing Lung Cancer-Related Anxiety (RELAX) (RELAX)

This is an interventional supportive care trial for Lung Cancer focused on measuring anxiety, Dyspnea, respiratory functioning Read More

Inclusion Criteria:

• Past History of any lung cancer
• For Stage I-III disease, patients should be 2-24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 12-week study and no evidence of disease.
• For Stage IV disease, patients may be receiving no treatment or may be receiving maintenance treatment with a target agent, chemotherapy, or immunotherapy provided the most recent imaging does not demonstrate progressive disease.
• After completion of all three screening questionnaires, participant must score accordingly on at least one questionnaire to be eligible.
• Willing/able to attend brief introductory session and use assigned device for the assigned period of time (15 minutes once or twice per day), at least 5 days per week for 12 weeks
• Age ≥ 18 years
• Must have telephone

Exclusion Criteria:

• Patient does not understand English
• Active lung infection
• Progressive cancer (must be considered no evidence of disease or stable)
• Any change in psychotropic medications in past 30 days
• Hearing loss that would preclude participating in interventions. Adequate hearing to participate will be determined via: (1) Response of "no" to the question ["Do you have a hearing problem now?"] Participants with hearing aids will be allowed to enroll as long as their hearing is adequate to hear the sounds on the study devices. If necessary, potential study participants will receive a brief test trial with the RESPeRATE device. If they indicate inability to hear the guiding tones, they will not be enrolled in the study.

Cortisol Exclusion

- Participants with endocrine disorders (e.g., diabetes and thyroid disorders) or on steroid-based medications are excluded from the cortisol portion of the study (with the exception of topical hydrocortisone that is permitted).